Final outcome results of platinum-sensitive small cell lung cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: A multi-institutional retrospective analysis.

7600 Background: Rechallenge might be used as rescue therapy in progressing platinum-sensitiveSmall Cell Lung Cancer (SCLC). This international multicenter retrospective analysis evaluates the clinical outcomes of SCLC patients treated with this strategy. Methods: We retrospectively collect each institutional data warehouse of platinum-sensitive SCLC treated with platinum/etoposide rechallenge. Primary endpoint was overall survival (OS) from diagnosis and from the rechallenge of chemotherapy (PPS). Secondary endpoints were response rate (RR) and Progression-Free Survival2 (PFS2) yielded by rechallenge. Results: We reviewed 2000 SCLC patients from 9 institutions. One hundred twelve (5.6%) with sensitive SCLC were treated with first-line platinum/etoposide rechallenge. There were 72 (64%) males and 40 (36%) females with a median age of 64 years (range 40–83). At diagnosis, 49 (44%) patients had limited disease (LD) whereas 63 (56%) had extensive disease (ED). ECOG Performance Score (PS) was 1 in 87%...